An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Property Value
dbo:abstract
  • Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. (en)
dbo:foundingYear
  • 1998-01-01 (xsd:gYear)
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 28902690 (xsd:integer)
dbo:wikiPageLength
  • 20060 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1114886378 (xsd:integer)
dbo:wikiPageWikiLink
dbp:foundation
  • 1998 (xsd:integer)
dbp:homepage
dbp:industry
  • Biopharmaceutical (en)
dbp:keyPeople
  • Matt Coffey Ph.D. - President, and Chief Executive Officer, Chief Operating Officer; Kirk Look, CA - Chief Financial Officer; Andres A. Gutierrez, M.D., Ph.D. - Chief Medical Officer; Andrew de Guttadauro, President, Oncolytics Biotech Inc. (en)
dbp:locationCity
dbp:locationCountry
dbp:name
  • Oncolytics Biotech Inc. (en)
dbp:products
  • REOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. (en)
dbp:tradedAs
  • , NASDAQ:ONCY (en)
dbp:type
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. (en)
rdfs:label
  • Oncolytics Biotech (en)
owl:sameAs
skos:closeMatch
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Oncolytics Biotech Inc. (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License